加载中
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.
前收盘价
US$4.52
−US$0.05 · -1.09%
盘前
US$4.52
US$0.00 · 0.00%
10月8日 9:00 ET
盘中时间采用ET。市场数据可能有所延迟。
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.
日内区间
当前US$4.52
52周区间
当前US$4.52
盘中时间采用ET。市场数据可能有所延迟。
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.
日内区间
当前US$4.52
52周区间
当前US$4.52
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | — | 9.3万 USD | 12万 USD | — | — |
| 销货成本 | — | 5万 USD | 7.7万 USD | 45.2万 USD | — |
| 毛利 | — | 4.3万 USD | 4.3万 USD | −45.2万 USD | — |
| 研究与开发 | 7453.6万 USD | 7047.1万 USD | 3803.8万 USD | 3435.4万 USD | 2643.5万 USD |
| 销售、一般及管理费用 | 2228万 USD | — | — | 1457.9万 USD | 1049.3万 USD |
| 营业费用 | 9681.6万 USD | 9357.4万 USD | 5087.9万 USD | 4893.3万 USD | 3692.8万 USD |
| 利息收入 | 154万 USD | 414.6万 USD | 126万 USD | 79.7万 USD | — |
| 利息支出 | — | — | — | — | 144.2万 USD |
| 折旧和摊销 | 112.9万 USD | 67.7万 USD | 28.6万 USD | 45.2万 USD | 67.6万 USD |
| 营业利润 | −9681.6万 USD | −9353.1万 USD | −5083.6万 USD | −4938.5万 USD | −3692.8万 USD |
| 净利润 | −1.41亿 USD | −6869.4万 USD | −7709.1万 USD | −4645.3万 USD | −3873.5万 USD |
公司数据更新于 2026年10月8日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$5.00
上涨空间 10.62%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2026年10月5日 | 1:12 | — | — |
已生效 2026年10月5日
1:12
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
